---
title: "NanFang Precision released its 2024 annual performance, with a net profit attributable to the parent company of 24.39 million yuan, a year-on-year decrease of 10.59%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237005255.md"
description: "According to the Zhitong Finance APP, NanFang Precision disclosed its annual report for 2024. During the reporting period, the company achieved revenue of 784 million yuan, a year-on-year increase of 16.80%; net profit attributable to shareholders was 24.39 million yuan, a year-on-year decrease of 10.59%; net profit excluding non-recurring items was 107 million yuan, a year-on-year increase of 23.69%; basic earnings per share were 0.0701 yuan. The company plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders"
datetime: "2025-04-22T14:54:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237005255.md)
  - [en](https://longbridge.com/en/news/237005255.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237005255.md)
generator: "portal-rs"
---

# NanFang Precision released its 2024 annual performance, with a net profit attributable to the parent company of 24.39 million yuan, a year-on-year decrease of 10.59%

According to the Zhitong Finance APP, NanFang Precision (002553.SZ) disclosed its annual report for 2024. During the reporting period, the company achieved revenue of 784 million yuan, a year-on-year increase of 16.80%; net profit attributable to shareholders was 24.39 million yuan, a year-on-year decrease of 10.59%; net profit excluding non-recurring items was 107 million yuan, a year-on-year increase of 23.69%; basic earnings per share were 0.0701 yuan. The company plans to distribute a cash dividend of 1 yuan (tax included) for every 10 shares to all shareholders

### Related Stocks

- [002553.CN](https://longbridge.com/en/quote/002553.CN.md)

## Related News & Research

- [Vector Science files US provisional patent for orthopedic tissue-regeneration peptide platform](https://longbridge.com/en/news/296483037.md)
- [Cell C publishes pro forma financials after Comm Equipment Company merger](https://longbridge.com/en/news/296585930.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)
- [Bucked Up® Launches Hunt: Orange Cream, a Limited-Edition Flavor Built to Fuel Your Hunt](https://longbridge.com/en/news/296524338.md)
- [XAU Resources signs option to buy 100% of Matthews Ridge gold project in Guyana, subject to 2% NSR](https://longbridge.com/en/news/296479350.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**